Your session is about to expire
← Back to Search
Topoisomerase I inhibitor
Irinotecan for Sarcoma
Phase 2
Waitlist Available
Research Sponsored by Herbert Irving Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Bidimensionally measurable disease on x-ray, MRI or CT scan, or physical exam (outside of previously irradiated area)
Creatinine less than ULN OR Creatinine clearance greater than 60 mL/min
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is studying how well irinotecan works in treating patients with stage IV or recurrent soft tissue sarcoma that has been previously treated with chemotherapy.
Who is the study for?
This trial is for adults with advanced soft tissue sarcoma that has returned or spread, and who have tried but didn't respond well to up to two chemotherapy treatments, including one with doxorubicin. They must have measurable tumor growth outside of previously treated areas and no cancer spread to the brain.Check my eligibility
What is being tested?
The study is testing the effectiveness of a chemotherapy drug called Irinotecan in patients with stage IV or recurrent soft tissue sarcoma. It's specifically for those whose disease progressed after previous chemotherapy treatments.See study design
What are the potential side effects?
Irinotecan can cause side effects like diarrhea, fatigue, hair loss, nausea, vomiting, low white blood cell count (increasing infection risk), anemia (low red blood cells), and decreased appetite.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My cancer can be measured on scans or physical exams.
Select...
My kidney function is normal or above 60 mL/min.
Select...
I do not have heart failure that needs treatment.
Select...
I do not have Gilbert's syndrome.
Select...
I've had 1-2 chemotherapy treatments, one with doxorubicin, for my cancer.
Select...
I am 18 years old or older.
Select...
My sarcoma is advanced and cannot be removed with surgery.
Select...
My cancer has not spread to my brain.
Select...
I do not have any ongoing or untreated infections.
Select...
I can take care of myself and am up and about more than 50% of my waking hours.
Select...
I have not had a heart attack in the last 6 months.
Select...
I do not have any physical, mental, or emotional health issues.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
Herbert Irving Comprehensive Cancer CenterLead Sponsor
33 Previous Clinical Trials
902 Total Patients Enrolled
4 Trials studying Sarcoma
25 Patients Enrolled for Sarcoma
Robert N. Taub, MD, PhDStudy ChairHerbert Irving Comprehensive Cancer Center
6 Previous Clinical Trials
82 Total Patients Enrolled
4 Trials studying Sarcoma
25 Patients Enrolled for Sarcoma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- It's been over 3 weeks since my last radiotherapy and I've recovered.My cancer can be measured on scans or physical exams.My kidney function is normal or above 60 mL/min.I do not have heart failure that needs treatment.I do not have Gilbert's syndrome.I am not receiving any other chemotherapy treatments.I am not currently on any hormonal therapy.I've had 1-2 chemotherapy treatments, one with doxorubicin, for my cancer.I am 18 years old or older.I have never been treated with irinotecan or topotecan.My sarcoma is advanced and cannot be removed with surgery.My cancer has not spread to my brain.I do not have any ongoing or untreated infections.I have been diagnosed with a specific type of sarcoma or mesothelioma.I can take care of myself and am up and about more than 50% of my waking hours.I have not had a heart attack in the last 6 months.I do not have any physical, mental, or emotional health issues.I haven't had any cancer in the past 5 years, except for certain skin cancers, cervical carcinoma in situ, or early-stage cancer that's now in complete remission.It has been over 4 weeks since my last surgery and I have recovered.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any open slots for volunteers in this research project?
"No, this study is not presently recruiting patients according to the information found on clinicaltrials.gov. This particular trial was posted on 7/1/1997 and was last edited on 1/3/2014; however, there are other trials that may be of interest as they are actively enrolling participants."
Answered by AI
Is this medication cleared by the FDA?
"While there is some evidence from Phase 2 trials to support the safety of this treatment, it has not been proven effective. Therefore, our team at Power estimates the safety of this treatment to be a 2."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger